At the midpoint of Eli Lilly and Company's (LLY) 2026 revenue guidance, $86 billion is the number every buy-side model will anchor on. The company has set a range of $85 billion to $87 billion for the year. What complicates the read is that Lilly is also expanding access through two programs, Foundayo and the Medicare GLP-1 Bridge, and the connection between those investments and the revenue range has not been quantified.
What the guidance says
The $85 billion to $87 billion range is a full-year 2026 projection. At that scale, it is a statement about aggregate trajectory. The guidance sets the bar against which every subsequent quarterly print will be measured.
The access programs
Alongside the revenue projection, Lilly is expanding access to its Foundayo program and its Medicare GLP-1 Bridge program. Both are described as access expansions. Revenue at $85 billion to $87 billion requires patient volume to hold; access programs are the mechanism Lilly is using to support that volume. The two disclosures, read together, are the argument the company is making.
The counterargument
The counterargument is execution. Expanding a program is an intention. Filling it is a result. Lilly has provided no enrollment figures for Foundayo or the Medicare GLP-1 Bridge program, which means the contribution of either to the guidance range is a model assumption rather than a verifiable input. Investors stress-testing the top end of that range will need patient start data that is not yet in the disclosures.
On balance, the $85 billion to $87 billion target is the headline and the access expansions are the stated path to it. Lilly has provided no enrollment figures for either program.